This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX debut, and Juncell’s Hong Kong IPO filing targeting China’s first TIL therapy. Biocytogen listed on Shanghai’s STAR Market for its antibody discovery platforms, while Formation Bio launched Bleecker Bio with a US$605M deal for Lynk Pharma’s TYK2 inhibitor. Sobi acquired Arthrosi for up to US$1.5B, adding the Phase III gout drug pozdeutinurad. Clinical updates feature InnoCare’s zurletrectinib for NTRK-positive solid tumors, CSPC’s semaglutide obesity filing, Junshi’s progress in myelofibrosis and breast cancer, ImmuneOnco’s strong IMM0306 data in lymphoma, and Innovent’s trispecific antibody IBI3003 for multiple myeloma.
